“Patient-centered” study seeks to assess quality of time that patients live by measuring the “treatment-free survival” outcome. A treatment combining two immunotherapies gave patients with advanced kidney cancer a longer time without subsequent treatment...
U.S. map spotlights industrial hot spots for cancer-causing air pollution, and surgery delays after initial treatment impact survival for some patients with locally advanced rectal cancer.
Aggressive treatments given to younger patients with B-cell non-Hodgkin lymphoma may leave them vulnerable to other diseases later in life, according to a study in the AACR journal Cancer Epidemiology, Biomarkers & Prevention.
Patient expenses for cancer care exceed $21 billion in 2019, the FDA introduces stringent requirements for breast implants and more news of the week from Cancer Today.
THE FDA GRANTED ACCELERATED APPROVAL TO A TARGETED THERAPY FOR PATIENTS WITH CML RESISTANT TO OTHER THERAPEUTICS The U.S. Food and Drug Administration (FDA) approved the drug asciminib (Scemblix) for certain patients with Philadelphia...
A couple reflect on how a cancer diagnosis affected their adoption journey, researchers suggest Black women get screened for breast cancer starting at age 40, and the U.S. FDA approved an immunotherapeutic as adjuvant...
Once considered undruggable, mutant KRAS has emerged in recent years as a viable target for anticancer therapeutics. As a member of the RAS superfamily of proteins, KRAS helps regulate cellular proliferation. When activated, KRAS upregulates proliferative pathways;...
Liver cancer is the second most common cause of cancer-related deaths worldwide. In 2021, it is estimated that more than 42,000 people will be diagnosed with the disease and approximately 30,000 will die because...
The FDA grants authorization for an e-cigarette for the first time, citing the benefits for people switching from traditional cigarettes, and more from Cancer Today magazine.
THE FDA APPROVED THE FIRST ADJUVANT IMMUNOTHERAPY FOR EARLY LUNG CANCER The U.S. Food and Drug Administration (FDA) granted expanded approval to atezolizumab (Tecentriq) to include the treatment of certain patients with early non-small...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now